<p>Kivexa is used with at least one other antiviral medicine to treat adults and children weighing at least 25 kg who are infected with human immunodeficiency virus (HIV), the virus that causes acquired immune deficiency syndrome (AIDS).</p><p>Kivexa contains two active substances, abacavir and lamivudine.</p>
Therapeutic Indication
<div class="subsection mt-3-5"> <h3>Therapeutic indication</h3><p>Kivexa is indicated in antiretroviral combination therapy for the treatment of Human Immunodeficiency Virus (HIV) infection in adults, adolescents and children weighing at least 25 kg.</p> <p>Before initiating treatment with abacavir, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient, irrespective of racial origin. Abacavir should not be used in patients known to carry the HLA-B*5701 allele.</p> </div>
Therapeutic Area (MeSH)
ATC Code
J05AR02
ATC Item
N/A
Pharmacotherapeutic Group
N/A
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| abacavir | N/A | abacavir |
| lamivudine | N/A | lamivudine |
EMA Name
Kivexa
Medicine Name
Kivexa
Aliases
N/ANo risk management plan link.
